{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:55:10Z","timestamp":1790765710380,"version":"4.1.0"},"reference-count":33,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are increasingly used for heart failure and chronic kidney disease beyond type 2 diabetes, increasing exposure among people without diabetes. Ketoacidosis is a recognized complication, but presentations at low blood glucose (&lt;100 mg\/dL) fall outside the familiar euglycemic diabetic ketoacidosis (DKA) alert and are easily missed. We aimed to describe the clinical phenotype of such cases; this review was not registered. Methods: We systematically searched PubMed and Web of Science (to 25 June 2026) and included only peer-reviewed case reports and case series describing ketoacidosis with a documented blood glucose &lt;100 mg\/dL at or near diagnosis during ongoing SGLT2 inhibitor use or within approximately two weeks after discontinuation. Reporting completeness was assessed with the CARE (Case Report) checklist; analyses were descriptive. Results: Fifteen cases met the criteria (median age 61 years; 6\/15 nondiabetic; 6\/15 receiving it for heart failure). Median glucose was 68 mg\/dL (n = 15; 10\/15 &lt;70). Metabolic acidosis was frequently marked (median pH 7.17 [n = 14], anion gap 19.9 [n = 13], \u03b2-hydroxybutyrate 5.0 mmol\/L [n = 11]). Fasting or poor oral intake was the commonest precipitant (11\/15). Among six cases with extractable timing, three occurred within 24 h. Blood glucose was not correlated with \u03b2-hydroxybutyrate in this small exploratory sample (Spearman \u03c1 = \u22120.20; n = 11; p = 0.56). One death occurred (aspiration). Conclusions: This descriptive synthesis characterizes ketoacidosis occurring at hypoglycemic and low glucose levels reported in SGLT2 inhibitor users, including nondiabetic and cardiorenal patients. The design cannot establish incidence, risk, or causality (very low certainty of evidence); clinicians should nonetheless consider ketoacidosis in exposed patients with anion-gap acidosis or ketosis even without hyperglycemia.<\/jats:p>","DOI":"10.3390\/jcm15197595","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:25:42Z","timestamp":1790760342000},"page":"7595","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ketoacidosis at Hypoglycemic and Low Glucose Levels Associated with SGLT2 Inhibitor Use: A Descriptive Systematic Review of Published Cases"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6860-9734","authenticated-orcid":false,"given":"Hideya","family":"Itagaki","sequence":"first","affiliation":[{"name":"Division of Emergency and Disaster Medicine, Tohoku Medical and Pharmaceutical University Hospital, 1-12-1 Fukumuro, Miyaginoku, Sendai 983-8512, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8462-8281","authenticated-orcid":false,"given":"Tomoyuki","family":"Endo","sequence":"additional","affiliation":[{"name":"Division of Emergency and Disaster Medicine, Tohoku Medical and Pharmaceutical University Hospital, 1-12-1 Fukumuro, Miyaginoku, Sendai 983-8512, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.annemergmed.2026.04.009","article-title":"SGLT-2 Use and Hypoglycemic Ketoacidosis","volume":"88","author":"Johnson","year":"2026","journal-title":"Ann. Emerg. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2337\/diacare.24.1.131","article-title":"Management of hyperglycemic crises in patients with diabetes","volume":"24","author":"Kitabchi","year":"2001","journal-title":"Diabetes Care"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"The EMPA-Kidney Collaborative Group, Herrington, W.G., Staplin, N., Wanner, C., Green, J.B., Hauske, S.J., Emberson, J.R., Preiss, D., Judge, P., and Mayne, K.J. (2023). Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med., 388, 117\u2013127.","DOI":"10.1056\/NEJMoa2204233"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jclinepi.2013.08.003","article-title":"The CARE guidelines: Consensus-based clinical case reporting guideline development","volume":"67","author":"Gagnier","year":"2014","journal-title":"J. Clin. Epidemiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/08971900241273169","article-title":"Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitor-Related Euglycemic Diabetic Ketoacidosis: A Case Series","volume":"38","author":"Meier","year":"2025","journal-title":"J. Pharm. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2324709617712736","DOI":"10.1177\/2324709617712736","article-title":"Euglycemic Diabetic Ketoacidosis with Prolonged Glucosuria Associated with the Sodium-Glucose Cotransporter-2 Canagliflozin","volume":"5","author":"Kelmenson","year":"2017","journal-title":"J. Investig. Med. High Impact Case Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"8882299","DOI":"10.1155\/2020\/8882299","article-title":"Euglycemic Ketoacidosis in a Patient with Metastatic Non-Small-Cell Lung Adenocarcinoma and Concomitant Pulmonary Embolism","volume":"2020","author":"Tyack","year":"2020","journal-title":"Case Rep. Endocrinol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2174\/1573399816666200316112709","article-title":"A Case Report: Euglycemic Diabetic Ketoacidosis Presenting as Chest Pain in a Patient on a Low Carbohydrate Diet","volume":"17","author":"Dorcely","year":"2021","journal-title":"Curr. Diabetes Rev."},{"key":"ref_14","first-page":"e24016","article-title":"An Unsuspected Case of Euglycemic Diabetic Ketoacidosis with Twists","volume":"14","author":"Kang","year":"2022","journal-title":"Cureus"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e01570","DOI":"10.1213\/XAA.0000000000001570","article-title":"Postoperative Ketoacidosis with Hypoglycemia in a Nondiabetic Patient Taking Dapagliflozin for Heart Failure: A Case Report","volume":"16","author":"Seki","year":"2022","journal-title":"A A Pract."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.mayocp.2023.04.003","article-title":"Alcoholic Ketoacidosis Manifesting with Hypoglycemia Exacerbated by an SGLT2 Inhibitor in a Nondiabetic Patient","volume":"98","author":"Iesaka","year":"2023","journal-title":"Mayo Clin. Proc."},{"key":"ref_17","first-page":"e52104","article-title":"Euglycemic Diabetic Ketoacidosis Presenting as Hypoglycemia in a Patient with Type 2 Diabetes and Von Gierke\u2019s Disease","volume":"16","author":"Tito","year":"2024","journal-title":"Cureus"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.4081\/itjm.2024.1716","article-title":"Sodium-glucose co-transporter-2 inhibitor-associated nondiabetic ketoacidosis: A case report","volume":"18","author":"Trapanese","year":"2024","journal-title":"Ital. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e01787","DOI":"10.14309\/crj.0000000000001787","article-title":"Empagliflozin-Induced Nondiabetic Ketoacidosis in Advanced Alcoholic Liver Disease","volume":"12","author":"Dhoop","year":"2025","journal-title":"ACG Case Rep. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s11739-025-04058-3","article-title":"Euglycemic ketoacidosis in a nondiabetic patient with Duchenne muscular dystrophy on dapagliflozin","volume":"20","author":"Mateu","year":"2025","journal-title":"Intern. Emerg. Med."},{"key":"ref_21","first-page":"148","article-title":"Beyond Glucose Levels: Redefining Diabetic Ketoacidosis-A Case of Hypoglycemic Diabetic Ketoacidosis","volume":"11","author":"Sydney","year":"2025","journal-title":"AACE Clin. Case Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jemermed.2025.02.018","article-title":"A Case of Concurrent Metformin-Associated Lactic Acidosis and Euglycemic Diabetic Ketoacidosis","volume":"75","author":"Tomita","year":"2025","journal-title":"J. Emerg. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.2169\/internalmedicine.4752-24","article-title":"Euglycemic Diabetic Ketoacidosis in a Patient with Type 2 Diabetes and Preserved Insulin Secretion on Empagliflozin","volume":"64","author":"Yoshida","year":"2025","journal-title":"Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.21037\/acr-2025-232","article-title":"Euglycemic diabetic ketoacidosis following sleeve gastrectomy in a patient with type 2 diabetes on a sodium-glucose co-transporter 2 inhibitor: A case report and call for practice guidelines","volume":"10","author":"Alsulaimi","year":"2026","journal-title":"AME Case Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00125-017-4301-8","article-title":"SGLT2 inhibitors and diabetic ketoacidosis: Data from the FDA Adverse Event Reporting System","volume":"60","author":"Fadini","year":"2017","journal-title":"Diabetologia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/fcp.12334","article-title":"SGLT-2 inhibitors and ketoacidosis: A disproportionality analysis in the World Health Organization\u2019s adverse drug reactions database","volume":"32","author":"Robin","year":"2018","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40261-020-00925-3","article-title":"Acute Renal Failure, Ketoacidosis, and Urogenital Tract Infections with SGLT2 Inhibitors: Signal Detection Using a Japanese Spontaneous Reporting Database","volume":"40","author":"Katsuhara","year":"2020","journal-title":"Clin. Drug Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2337\/dc07-1683","article-title":"Can serum beta-hydroxybutyrate be used to diagnose diabetic ketoacidosis?","volume":"31","author":"Karon","year":"2008","journal-title":"Diabetes Care"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/dc09-9032","article-title":"Hyperglycemic crises in adult patients with diabetes","volume":"32","author":"Kitabchi","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_32","unstructured":"U.S. Food and Drug Administration (2026, September 16). FDA Revises Labels of SGLT2 Inhibitors for Diabetes to Include Warnings About Too Much Acid in the Blood and Serious Urinary Tract Infections. FDA Drug Safety Communication. 2015 (Updated 2020), Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/anae.16541","article-title":"Elective peri-operative management of adults taking glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide agonists and sodium-glucose cotransporter-2 inhibitors: A multidisciplinary consensus statement","volume":"80","author":"Dhesi","year":"2025","journal-title":"Anaesthesia"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7595\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:56:21Z","timestamp":1790762181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":33,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["jcm15197595"],"URL":"https:\/\/doi.org\/10.3390\/jcm15197595","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]}}}